The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer.

Grinshpun A, Tolaney SM, Burstein HJ, Jeselsohn R, Mayer EL.

Open source

DOI: 10.1038/s41523-023-00520-7
Published: 2023-03-22
Container: NPJ Breast Cancer
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41523-023-00520-7,
  title = {The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer.},
  author = {Grinshpun A and  Tolaney SM and  Burstein HJ and  Jeselsohn R and  Mayer EL.},
  year = {2023},
  journal = {NPJ Breast Cancer},
  doi = {10.1038/s41523-023-00520-7},
  url = {https://doi.org/10.1038/s41523-023-00520-7}
}

RIS

TY  - JOUR
TI  - The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer.
AU  - Grinshpun A
AU  -  Tolaney SM
AU  -  Burstein HJ
AU  -  Jeselsohn R
AU  -  Mayer EL.
PY  - 2023
JO  - NPJ Breast Cancer
DO  - 10.1038/s41523-023-00520-7
UR  - https://doi.org/10.1038/s41523-023-00520-7
ER  -

APA

A, G., SM, T., HJ, B., R, J., & EL., M. (2023). The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer.. NPJ Breast Cancer. https://doi.org/10.1038/s41523-023-00520-7

Source records

europe-pmc · retrieved 2026-09-26T21:23:13.474Z
doaj · retrieved 2026-09-26T21:23:13.472Z